We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Early Treatment Initiation With Oral Prednisolone for Relapse Prevention Alleviates Depression and Fatigue in Aquaporin-4–Positive Neuromyelitis optica Spectrum Disorder.
- Authors
Akaishi, Tetsuya; Takahashi, Toshiyuki; Fujihara, Kazuo; Misu, Tatsuro; Fujimori, Juichi; Takai, Yoshiki; Nishiyama, Shuhei; Abe, Michiaki; Ishii, Tadashi; Aoki, Masashi; Nakashima, Ichiro
- Abstract
Background: Neuromyelitis optica spectrum disorder (NMOSD) is a relapsing autoimmune-related neurological disorder of the central nervous system. Most patients with NMOSD have serum anti-aquaporin-4 immunoglobulin G antibodies (AQP4-IgG). In addition to optic neuritis and myelitis, other insidious symptoms such as depressive state and chronic fatigue in NMOSD are gradually being recognized. Methods: To elucidate the impact of low- to medium-dose oral prednisolone (PSL) as a relapse prevention therapy for psychiatric disturbances and chronic fatigue in NMOSD, we evaluated clinical data from 39 patients with AQP4-IgG-positive NMOSD, along with the details of present and cumulative oral PSL dosage. Results: Thirty-six of the 39 patients were treated with low- to medium-dose oral PSL, and the mean and standard deviation of the present daily dose of oral PSL were 7.9 ± 4.0 mg/day. None of the patients were treated with a daily PSL dose of >15 mg. As a result, the disease duration and the untreated period before starting oral PSL showed weak to moderate correlations with the subsequent severities of psychiatric disturbance and fatigue level. Meanwhile, none of the other treatment-related variables evaluated, such as the present oral PSL daily dose, cumulative PSL dose, months of oral PSL administration, previous courses of steroid pulse therapy, and coadministered immunosuppressants, were correlated with these insidious symptoms. Conclusion: Our results suggest that the use of long-term low- to medium-dose oral PSL ≤15 mg daily for relapse prevention in AQP4-IgG-positive NMOSD would not aggravate the psychiatric and fatigue conditions. On the contrary, early initiation of oral PSL for relapse prevention, together with significantly decreased relapse rate, alleviated the subsequent depressive state and fatigue from the disease.
- Subjects
NEUROMYELITIS optica; OPTIC neuritis; FATIGUE (Physiology); CENTRAL nervous system; PREDNISOLONE; MINDFULNESS-based cognitive therapy; SUBSTANCE abuse relapse
- Publication
Frontiers in Neurology, 2021, Vol 11, pN.PAG
- ISSN
1664-2295
- Publication type
Article
- DOI
10.3389/fneur.2021.608149